Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,396 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative whole-genome and proteomics analyses of the next seed bank and the original master seed bank of MucoRice-CTB 51A line, a rice-based oral cholera vaccine.
Sasou A, Yuki Y, Honma A, Sugiura K, Kashima K, Kozuka-Hata H, Nojima M, Oyama M, Kurokawa S, Maruyama S, Kuroda M, Tanoue S, Takamatsu N, Fujihashi K, Goto E, Kiyono H. Sasou A, et al. Among authors: sugiura k. BMC Genomics. 2021 Jan 19;22(1):59. doi: 10.1186/s12864-020-07355-7. BMC Genomics. 2021. PMID: 33468052 Free PMC article.
Characterization and Specification of a Trivalent Protein-Based Pneumococcal Vaccine Formulation Using an Adjuvant-Free Nanogel Nasal Delivery System.
Yuki Y, Uchida Y, Sawada SI, Nakahashi-Ouchida R, Sugiura K, Mori H, Yamanoue T, Machita T, Honma A, Kurokawa S, Mukerji R, Briles DE, Akiyoshi K, Kiyono H. Yuki Y, et al. Among authors: sugiura k. Mol Pharm. 2021 Apr 5;18(4):1582-1592. doi: 10.1021/acs.molpharmaceut.0c01003. Epub 2021 Feb 23. Mol Pharm. 2021. PMID: 33621107 Free article.
Development of Antibody-Fragment-Producing Rice for Neutralization of Human Norovirus.
Sasou A, Yuki Y, Kurokawa S, Sato S, Goda Y, Uchida M, Matsumoto N, Sagara H, Watanabe Y, Kuroda M, Sakon N, Sugiura K, Nakahashi-Ouchida R, Ushijima H, Fujihashi K, Kiyono H. Sasou A, et al. Among authors: sugiura k. Front Plant Sci. 2021 Feb 23;12:639953. doi: 10.3389/fpls.2021.639953. eCollection 2021. Front Plant Sci. 2021. PMID: 33868338 Free PMC article.
Oral MucoRice-CTB vaccine is safe and immunogenic in healthy US adults.
Yuki Y, Nojima M, Kashima K, Sugiura K, Maruyama S, Kurokawa S, Yamanoue T, Nakahashi-Ouchida R, Nakajima H, Hiraizumi T, Kohno H, Goto E, Fujihashi K, Kiyono H. Yuki Y, et al. Among authors: sugiura k. Vaccine. 2022 May 26;40(24):3372-3379. doi: 10.1016/j.vaccine.2022.04.051. Epub 2022 Apr 26. Vaccine. 2022. PMID: 35484039 Free article. Clinical Trial.
MucoRice-CTB line 19A, a new marker-free transgenic rice-based cholera vaccine produced in an LED-based hydroponic system.
Yuki Y, Kurokawa S, Sugiura K, Kashima K, Maruyama S, Yamanoue T, Honma A, Mejima M, Takeyama N, Kuroda M, Kozuka-Hata H, Oyama M, Masumura T, Nakahashi-Ouchida R, Fujihashi K, Hiraizumi T, Goto E, Kiyono H. Yuki Y, et al. Among authors: sugiura k. Front Plant Sci. 2024 Mar 15;15:1342662. doi: 10.3389/fpls.2024.1342662. eCollection 2024. Front Plant Sci. 2024. PMID: 38559768 Free PMC article.
1,396 results